Shares of Quest Diagnostics Inc. DGX slid 1.71% to $172.01 Wednesday, on what proved to be an all-around positive trading ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

A Wall Street analyst issued contrasting ratings on Tuesday for two major diagnostic testing companies, upgrading shares of ...

Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.

Fintel reports that on March 4, 2025, Citigroup downgraded their outlook for Quest Diagnostics (NYSE:DGX) from Buy to Neutral ...

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned ...

Charles River Labs (CRL) stock and LabCorp (LH) stock were upgraded and Quest Diagnostics (DGX) stock was downgraded at Citi.

Fresenius Medical Care plans to sell select assets of Spectra Laboratories to Quest Diagnostics as it exits non-core markets.

Quest Diagnostics DGX has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain.

In an age of capitation and value-based care, health plans must work harder than ever to offer tailored support to higher-risk members with chronic conditions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Quest Diagnostics Inc. DGX shed 1.10% to $175.01 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...